|
|
Article: Acadia seeking big-pharma partner for promising drug: ACP-103 could aid schizophrenia, insomnia.
- Article from:
- San Diego Business Journal
- Article date:
- March 26, 2007
- Author:
CopyrightCOPYRIGHT 2007 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Acadia Pharmaceuticals Inc. is hoping to keep the momentum going after better-than-expected results from a clinical trial for its schizophrenia drug made its stock price double.
The firm is seeking a large pharmaceutical partner to help it garner a chunk of the $15 billion schizophrenia drug market.
Chief Executive Officer Uli Hacksell said a big-pharma partner would help boost Acadia's drug, known as ACP-103, as it moves into third stage human clinical trials--the last required tests before consideration from the Food and Drug Administration.
Success comes two ways in the biotech world--sporadically, as in the case of positive clinical trial ...